MX2021005611A - Control de metales traza durante la produccion de anticuerpos anti-cd38. - Google Patents

Control de metales traza durante la produccion de anticuerpos anti-cd38.

Info

Publication number
MX2021005611A
MX2021005611A MX2021005611A MX2021005611A MX2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A
Authority
MX
Mexico
Prior art keywords
antibodies
during production
control
trace metals
metals during
Prior art date
Application number
MX2021005611A
Other languages
English (en)
Inventor
Nicole Larmore
Balasubramanian Ramanathan
Richard Yeager
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021005611A publication Critical patent/MX2021005611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción se relaciona con métodos para controlar metales traza durante la producción de anticuerpos anti-CD38, sustancias farmacológicas y productos farmacológicos generados usando los métodos, y usos de las sustancias farmacológicas y productos farmacológicos generados.
MX2021005611A 2018-11-13 2019-11-13 Control de metales traza durante la produccion de anticuerpos anti-cd38. MX2021005611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760782P 2018-11-13 2018-11-13
PCT/IB2019/059766 WO2020100073A1 (en) 2018-11-13 2019-11-13 Control of trace metals during production of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
MX2021005611A true MX2021005611A (es) 2021-06-30

Family

ID=70551717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005611A MX2021005611A (es) 2018-11-13 2019-11-13 Control de metales traza durante la produccion de anticuerpos anti-cd38.

Country Status (14)

Country Link
US (1) US11634499B2 (es)
EP (1) EP3880824B1 (es)
JP (2) JP2022513018A (es)
KR (1) KR20210091763A (es)
CN (1) CN113015805A (es)
AU (1) AU2019379858B2 (es)
CA (1) CA3117447C (es)
EA (1) EA202191352A1 (es)
IL (1) IL282970A (es)
MA (1) MA54248A (es)
MX (1) MX2021005611A (es)
SG (1) SG11202104092UA (es)
TW (1) TW202039849A (es)
WO (1) WO2020100073A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP4219561A3 (en) 2015-05-20 2023-11-08 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
MA43187B1 (fr) * 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
CN113015805A (zh) 2018-11-13 2021-06-22 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
EP0082974B1 (en) 1981-12-24 1986-05-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
ES2344789T5 (es) 2003-05-15 2017-06-14 Wyeth Llc Alimentación restringida de glucosa para el cultivo de células animales
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
US9062106B2 (en) * 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN105392878A (zh) * 2013-07-23 2016-03-09 百康有限公司 用于控制蛋白质中的岩藻糖基化水平的方法
US20150139988A1 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016017660B1 (pt) * 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
US10844416B2 (en) * 2015-06-01 2020-11-24 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN113015805A (zh) 2018-11-13 2021-06-22 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制

Also Published As

Publication number Publication date
MA54248A (fr) 2021-09-22
KR20210091763A (ko) 2021-07-22
SG11202104092UA (en) 2021-05-28
BR112021008879A2 (pt) 2021-10-26
IL282970A (en) 2021-06-30
EP3880824A4 (en) 2022-08-10
US11634499B2 (en) 2023-04-25
CA3117447C (en) 2024-06-04
AU2019379858B2 (en) 2024-01-04
WO2020100073A1 (en) 2020-05-22
EP3880824B1 (en) 2024-07-24
AU2019379858A1 (en) 2021-05-20
CN113015805A (zh) 2021-06-22
EA202191352A1 (ru) 2021-08-11
JP2024129019A (ja) 2024-09-26
JP2022513018A (ja) 2022-02-07
US20200148782A1 (en) 2020-05-14
TW202039849A (zh) 2020-11-01
CA3117447A1 (en) 2020-05-22
EP3880824A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
MX2021005611A (es) Control de metales traza durante la produccion de anticuerpos anti-cd38.
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12017501365B1 (en) Novel promoter and uses thereof
PH12017501042A1 (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12020550529A1 (en) Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine
MX2021014888A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda.
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
TW201612319A (en) Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
EP3391965A4 (en) RADICALLY DEVELOPING CATALYST, METHOD FOR PRODUCING A RADICAL, METHOD FOR PRODUCING AN OXIDATION REACTION PRODUCT, MEDICAMENTS AND MEDICAMENTS FOR AGRICULTURE AND LIVESTOCK
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2020004093A (es) Puzolana de vidrio activada.
MX2019009136A (es) Aparato y proceso de flujo continuo para la produccion de derivado de acido boronico.
MX2018013334A (es) Metodo para producir derivados de espirociclicos cis-alcoxi-sustituidos 1-h-pirrolidina-2,4-diona.
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
MX2017000519A (es) Derivados de azaspiro(4.5)decano sustituido.